作者: Giorgio Bolis , Giovanna Scarfone , Giorgio Giardina , Antonella Villa , Giorgia Mangili
关键词: Cisplatin 、 Randomization 、 Urology 、 Carboplatin 、 Chemotherapy 、 Ovarian cancer 、 Surgery 、 Carcinoma 、 Discontinuation 、 Leukopenia 、 Medicine 、 Obstetrics and gynaecology 、 Oncology
摘要: Abstract Objective. The aim of the study was to analyze benefit/toxicity profile a second-line treatment with carboplatin alone or plus another non-cross-resistant drug (epidoxorubicin) in ovarian cancer patients sensitive cisplatin-based chemotherapy at first-line treatment. Methods. We conducted randomized clinical trial. Women epithelial FIGO Stage II–IV who had complete partial response cisplatin carboplatin-based regiments and subsequently progressed relapsed more than 6 months after discontinuation were eligible for study. A total 190 subjects entered They randomly allocated either 300 mg/m 2 every 28 days five cycles (95 patients) 120 epidoxorubicin patients). Results. reported, respectively, 32 (36%) women (31.8%) those epidoxorubicin. corresponding figures 18 (20.2%) 26 (29.9%). Comparing frequency response, no change, progression, differences between two groups not significant (χ 3 5.10, P = 0.16). median duration 16 20 group ( significant). 3-year percentage survival 29% 42% group; this difference statistically significant. leukopenia, anemia, thrombocytopenia grade 3–4 higher group. Alopecia G3 present 88% treated carboplatin. Conclusions. general results do show any marked among single-agent (carboplatin) multiagent (carboplatin epidoxorubicin) schedules. Toxicity, particularly hematological, relevant schedule.